Skip to Main Content

An official website of the United States government

Here you can browse the complete list of projects for PLCO whose requests for data/biospecimens were approved.

Name Principal Investigator Institution Study Date Approved Project ID
Aflatoxin, Polycyclic Aromatic Hydrocarbons, Heavy metals and DNA Methylation in Hepatocellular Carcinoma HuiChen Wu Columbia University PLCO Sep 7, 2022 2022-0003
The timing between the diagnosis and the end of the last treatment in the cancer continuum in patients with lung cancer by TNM stages; and the impact of delays in the final survival of the patients, in PLCO, In the period available in the data set. Percy Guzman NCI PLCO Sep 6, 2022 PLCO-1036
Post-diagnosis exercise and mortality risk in cancer survivors Jessica Gorzelitz University of Iowa PLCO Sep 6, 2022 PLCO-1032
Prostate specific antigen volatility and the diagnosis of clinically significant prostate cancer John Leppert Stanford University PLCO Aug 29, 2022 PLCO-1034
Metabolic health phenotypes, accelerated biological aging and cancer risk. Prasoona Karra Geisel School of Medicine at Dartmouth College PLCO Aug 29, 2022 PLCO-1028
Use of PLCO data to evaluate the performance of cancer risk models Thomas Ahearn Division of Cancer Genetics and Epidemiology, NCI PLCO Aug 22, 2022 PLCO-1025
Data Analysis of Male Breast Cancer Vaidehi Gajera Western Sydney University PLCO Aug 22, 2022 PLCO-1029
Identifying risk factors for depression and the role of depression in cancer Lei Zhang Uniformed Services University PLCO Aug 22, 2022 PLCO-1027
Prediction of Absolute Risk of Ovarian and Endometrial Cancer Sokbom Kang National Cancer Center, Korea PLCO Aug 22, 2022 PLCO-1023
Determination of the association between BDNF, a potential biomarker, and depression in patients with cancer Lei Zhang Uniformed Services University PLCO Aug 22, 2022 PLCO-1021
Fatty acids intake with emphasis on trans fatty acids and risks of Breast cancer and Colorectal Cancer Paolo Boffetta The Department of Medical and Surgical Sciences (DIMEC), the University of Bologna PLCO Aug 22, 2022 PLCO-1018
Bladder Cancer Data Visualization OMAR GALDAMEZ CRUZ CENTRO DE DISEÑO Y COMUNICACION, S.C. PLCO Aug 2, 2022 PLCO-1011
Prognostic factors in HER2-positive breast cancer Reem Chamseddine Weill Cornell Medicine-Qatar PLCO Aug 2, 2022 PLCO-1014
Clarifying the relationship between body mass index and lung cancer using causal inference methods Rajat Das Gupta University of South Carolina PLCO Aug 2, 2022 PLCO-1010
A Phase II extension of the use of cg05575921 Methylation to predict risk for lung cancer Robert Philibert Behavioral Diagnostics PLCO Aug 1, 2022 2022-0014
Characterization of serum immuno-oncology biomarker levels in PLCO participants with mosaic chromosomal alterations Mitchell Machiela National Cancer Institute PLCO Aug 1, 2022 2022-0022
Survival Analysis and the Effect of Censoring for Lung Cancer Azar Shahraz AstraZeneca PLCO Jul 22, 2022 PLCO-991
Identification of Risk Factors and Patient Populations at Risk for Developing Cancer of the Head and Neck Jay Piccirillo Washington University School of Medicine in St. Louis PLCO Jul 14, 2022 PLCO-1003
Screening for ovarian cancer in women with a personal or family history of breast or ovarian cancer Nathan Bromham National Institute for Health and Care Excellence PLCO Jul 12, 2022 PLCO-1002
Developing a multi-marker diagnostic test with predictive model enhancements for early-stage (Stage-1) Ovarian cancer Srinagesh Satyanarayana Kaya17 PLCO Jul 1, 2022 PLCO-1000